ArticleBMC women's health2025
Incidence of different histologic subtype of ovarian cancer in China: a population-based cancer registry study.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferent histologic subtypes of ovarian cancer have distinct risk factors, clinical features, and prognosis. This analysis intends to examine the regional differences in the incidence rates of different histologic subtypes of ovarian cancer in China and the changes in incidence in different age groups.
methodsData on ovarian cancer in China from the Cancer Incidence in Five Continents, Volume XII database between 2013 and 2017 were employed in this descriptive study. The age-standardized incidence rates (ASR) of ovarian cancer for serous carcinoma (SC), mucinous carcinoma (MC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), and other unidentified subtypes were calculated. The crude incidence rates of ovarian cancer in different age groups were calculated. Regional differences were analyzed using the six major administrative regions (Northeast, North China, Northwest, East China, Central South, and Southwest) and 20 provincial administrative regions, respectively.
resultsA total of 32,817 ovarian cancer patients were included, among which 7,742 (23.59%) had SC, 1,709 (5.21%) had MC, 1,319 (4.02%) had CCC, 1,233 (3.76%) had EC, and 20,814 (64.42%) had unclassified histologic subtypes. The ASR was 5.31 (95%CI: 5.26-5.37) per 100,000 people for overall ovarian cancer, 1.27 (95%CI: 1.24-1.29) for SC, 0.30 (95%CI: 0.28-0.31) for MC, 0.21 (95%CI: 0.20-0.22) for EC, 0.22 (95%CI: 0.21-0.23) for CCC, and 0.47 (95%CI: 0.47-0.48) for unclassified subtypes. There were differences in the distribution of subtypes in different regions of China: SC and CCC occurred most in the Northeast and North China, MC in the Northeast and Central South, and EC in the North China and Central South. The distribution of subtypes also varied across economic level regions, with higher frequencies of SC, CCC, and EC in the high economic level group. Furthermore, the crude incidence rates of SC subtypes in China increased with age, but showed a decreasing trend at age 60 years. The crude incidence rates of CCC, EC, MC, and other subtypes do not change distinctly with age.
conclusionThis study explored the incidence distribution of histologic subtypes of ovarian cancer in China, which may provide a reference for the screening, prevention, and control of the disease in the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.